Dyax news from FierceBiotech
NewsALSO NOTED: Dyax to close R&D facility;Nastech sells shares; and much more...
> Dyax says it plans to close its research facility in Belgium as it focuses on commercializing DX-88 to treat hereditary angioedema. Read more...
Dyax forges $231M development deal for DX-88
Cubist Pharmaceuticals has agreed to pay Dyax $15 million upfront and up to $216.5 million more in potential milestone payments for collaboration rights to Dyax's experimental therapy for the Read more...
Sanofi to pay $500M for Dyax antibody program
Sanofi-Aventis has committed up to $500 million for the worldwide rights to Dyax's DX-2240 human monoclonal Read more...
ALSO NOTED: Cross Country expands research offering; Dyax prices shares; Sciele takes stake in Addrenex; and much more...
> Cross Country Healthcare is buying Assent Consulting for $19.6 million in a deal designed to expand its biotech research services. Release Read more...
Analysts see a continuing surge of licensing dealsMerck officials would probably be among the first to agree with Needham & Associates' conclusion that the pace of biotech partnerships shows no sign of letting up. Big Pharma and Big Biotech are both avid about doing more deals to fill their pipelines. Among some of the biggest partnership deals that are likely in the works right now, they say, is a pact for Dendreon's Provenge, Dyax's … Read more...ALSO NOTED: Intradigm completes $16M Series A financing; Prana to raise $6M to fund trial; and much more...> Intradigm Corporation has completed a $16 million Series A financing, and has also relocated company headquarters to Palo Alto, CA from Rockville, MD. Intradigm is developing RNAi technology--a hot field which has seen a number of deals as of late. Release > Australia-based Prana Biotechnology announced that it will raise $6 million from investors to … Read more...Jerini drug for HAE produces mixed resultsGermany's Jerini is touting half of the results from two pivotal Phase III trials for Icatibant, an experimental subcutaneous treatment of hereditary angioedema (HAE). In one study, the primary endpoint was reached, showing a significant reduction in the time to onset of symptom relief. A second Phase III study, though, failed to hit its primary endpoint. The primary endpoint of median time to onset of symptom relief in the second trial was 2.5 hours for Icatibant versus 4.6 hours for … Read more...DEALS: GSK, ChemoCentryx ink $1.5B pact
Dyax pockets $30M in revenue dealCambridge, MA-based Dyax has snared a $30 million payment from Paul Capital Partners in exchange for a portion of the revenue generated by its Phage Display Licensing and Funded Research Program. Dyax can earn another $5 million based on revenue goals covering the next two years. In late July Dyax reported widened losses for its second quarter following the termination of its collaboration with Debiopharm. "This financing structure allows Dyax to unlock the value of future … Read more... | Press ReleasesDyax Announces Intent to Close Belgium Research Facility Dyax Announces Intent to Close Belgium Research Facility 4/28/2008 CAMBRIDGE, Mass. -- Dyax announced today that the Board of Directors of its Belgian subsidiary, Dyax SA, has initiated discussions Read more... |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets